The United Kingdom and the United States have concluded a significant trade agreement that will keep no duties on UK drug exports entering the American market.
Agreement Details of the Pact
Under the terms of the agreement, the UK has pledged to increase spending on pharmaceuticals through the public health system. This commitment secures that duties on these crucial exports will stay at zero for a period of the next three years.
This development comes after recent threats to significantly raise duties on patented pharmaceutical products, with potential rates mentioned as high as 100%.
"This arrangement between the United Kingdom strengthens the global environment for innovative medicines and introduces long-overdue fairness to transatlantic drug exports," a statement noted.
Economic Importance
Pharmaceuticals constitute one of the the United Kingdom's most significant goods shipped to the US, which is clearly the largest buyer for major companies like GSK and AstraZeneca.
Trade data reveal that in the 12 months to the end of the third quarter, the UK shipped pharmaceutical products valued at billions to the US. This amount represented nearly one-fifth of total UK exports in that timeframe.
"This guarantee safeguards work, stimulates funding and facilitates the UK to emerge as a international leader for medical research," the Business and Trade Secretary remarked.
Specific UK Commitments
The deal entails several specific pledges from the United Kingdom:
- Price Threshold Increase: The UK will increase the price threshold at which it judges new treatments to be prohibitively costly by 25%.
- Higher Drug Budget: There is a aim to double total health service expenditure on medicines from 0.3 percent of Gross Domestic Product to 0.6 percent over the next decade.
- Payback Limit: The percentage manufacturers must refund to the NHS to stay within budget will be capped at fifteen percent. Last year, rebates topped twenty percent.
Recent Tensions
The pact follows a protracted tension between the sector and the British authorities over medicine costs and approval rates.
The disagreement were heightened by arguments that American patients were paying a premium for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been halted or abandoned, while multi-billion-dollar funding commitments have been pledged toward projects in the United States.
One official acknowledged that the NHS must increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its total funding over the previous ten-year period.
